SPH4336 plus hormone therapy for breast cancer that has spread to the brain
Tests SPH4336 with hormone therapy in people with breast cancer brain metastases.
Key facts
- Who runs it
- Shanghai Pharmaceuticals Holding Co., Ltd
- Where
- China25 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 52 people, planned
- Started
- 19 Sept 2023
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional
- Treatments tested
- SPH4336 Tablets
- Record updated
- 5 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with HR-positive, HER2-negative breast cancer that has spread to the brain. They will take SPH4336 with hormone (endocrine) therapy.
- Age
- 18 to 75 years
- Sex
- Women only
- Disease stage
- Locally advanced or metastatic breast cancer with brain metastases, which cannot be treated with radical surgery or other local treatments. At least one tumour that can be measured. Able to do daily activities (ECOG 0 or 1). Expected to live at least 3 months.
- Earlier treatment
- People who got other experimental drugs in a clinical trial before the study treatment cannot join.
- Biomarker or test result
- HR-positive, HER2-negative
Main reasons for not taking part
- Inflammatory breast cancer, or a doctor finds endocrine therapy is not right for the person
- Other cancer in the past
- Pregnant or breastfeeding
- Serious heart disease, such as heart attack, heart failure or ejection fraction ≤ 50%, or past ischemic stroke
- Active hepatitis B or C, or known HIV infection
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Patients who voluntarily participate in this study, completely understand this study, and voluntarily sign the informed consent form (ICF)
- ECOG (Eastern Cooperative Oncology Group) performance status score of 0 or 1
- Life expectancy ≥ 3 months
- Patients with locally advanced or metastatic breast cancer who are unable to receive radical surgeries/other local therapies
- At least one measurable lesion
- Laboratory test results meet the relevant requirements for organ function
- Subjects who agree to take effective contraceptive measures
Who cannot take part
- Patients unsuitable for endocrine therapy at the investigator's discretion
- Patients who underwent a surgery prior to the start of study treatment, and have not yet recovered from adverse reactions of the surgery
- Patients who participated in a clinical trial and received other investigational drugs before the start of study treatment
- History of severe allergic diseases, history of severe drug allergies, or known allergy to any ingredient of the investigational product
- Presence of other diseases that the risks of receiving the study treatment outweigh its benefits, as determined by the investigator, or any other reason for which patients are ineligible for the study as assessed by the investigator
- Inflammatory breast cancer
- Have a History of other malignancies prior to the start of study treatment
- History of ischemic stroke or severe thromboembolic disease before the start of study treatment
- Hepatitis B surface antigen positive and HBV (Hepatitis B Virus) DNA > 2,000 IU/mL or > 10(4) copies/mL; HCV (Hepatitis C Virus) antibody positive and HCV RNA positive; or known HIV infection
- Presence of diseases or conditions that may impact drug administration or gastrointestinal absorption before the start of study treatment
- Presence of uncontrolled infections before the start of study treatment
- Known history of drug abuse, excessive drinking, or illegal drug use; history of confirmed neurological or mental disorders
- History of myocardial infarction, unstable angina pectoris, severe arrhythmia, and symptomatic congestive heart failure before the start of study treatment; ≥ NYHA (New York Heart Association) Class II; QTcF≥ 470 ms; left ventricular ejection fraction ≤ 50%
- Taking anti-tumor traditional Chinese patent medicines at the time of signing the ICF
- Pregnant or lactating women
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in breast cancer Patients with brain metastases.
The group in the trial
- SPH4336 TabletsTreatment being tested
SPH4336 Tablets; Letrozole tablets; Fulvestrant; Exemestane
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase II Study of SPH4336 in Combination With Endocrine Therapy in HR-positive, HER2-negative Breast Cancer Patients With Brain Metastases.
- Plain-language title
- SPH4336 plus hormone therapy for breast cancer that has spread to the brainGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT05872347, who can take part
- Record updated
- 5 May 2026